Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene TherapyMarketBeat · 16 hr ago
Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy TranscriptSeeking Alpha · 2 days ago
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACMGlobeNewsWire · 5 days ago
Lexeo Therapeutics to Participate in the Chardan Healthcare ConferenceGlobeNewsWire · Oct 8, 2026
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)GlobeNewsWire · Oct 1, 2026
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaPRNewsWire · Sep 23, 2026Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.29 | -$0.30 | Miss |
| May 11, 2026 | -$0.29 | -$0.25 | Beat |
| Mar 30, 2026 | -$0.32 | -$0.27 | Beat |
| Nov 5, 2025 | -$0.48 | -$0.33 | Beat |
| Aug 14, 2025 | -$0.64 | -$0.60 | Beat |
| May 12, 2025 | -$0.80 | -$0.99 | Miss |